About The Gazette Search Back Issues Contact Us    
The newspaper of The Johns Hopkins University April 25, 2005 | Vol. 34 No. 31
More Evidence Suggests Statins Cut Risk for Advanced Prostate Cancer

By Vanessa Wasta
Johns Hopkins Medicine

In a 10-year study of more than 30,000 health professionals, researchers at Johns Hopkins and Harvard found that the longer men take cholesterol-lowering drugs such as statins, the far less likely they are to develop advanced prostate cancer.

"We found that statin-takers cut their risk for advanced disease in half," said Elizabeth Platz, assistant professor at Johns Hopkins' Bloomberg School of Public Health and Kimmel Cancer Center.

Although earlier, smaller studies have linked the use of statins to a lower risk of prostate and other cancers, such as breast and colon, this is the first to tie risk reduction to prostate cancer stage while tracking the medication use before study participants got cancer.

Still, the researchers caution that data are not conclusive enough to warrant prescribing the drug to reduce cancer risk alone because many questions still linger, such as how statins might contribute to delaying the cancer process more effectively than nonstatins.

"Additional large studies may help confirm these results, but we also have some very important questions lingering as to which biochemical processes may link statins and reduced prostate cancer development," Platz said. "Instead of preventing cancer, statins might work by stalling a tumor already in the prostate, helping to ensure that it doesn't get worse."

Platz noted that "when cholesterol-lowering drugs first came onto the market almost 20 years ago, there was even concern that they might increase the risk of cancer. Now, we are seeing more evidence that the opposite may be the case, but more research needs to be done."

Platz presented results of her study April 18 at the American Association for Cancer Research annual meeting.

In their study, the researchers tracked use of cholesterol-lowering drugs (including statins and nonstatins) and prostate cancer diagnosis among a group of 34,438 male health professionals, including dentists and veterinarians.

They found no association between use of cholesterol-lowering drugs and whether or not men were diagnosed with early, curable forms of prostate cancer. But they did find that men who took cholesterol-lowering medications, as opposed to those not taking them, had half the risk of eventually developing advanced prostate cancers (283 men had cancer that invaded nearby tissue, had spread to other parts of the body or was fatal) and one-third the risk of the most serious type of advanced prostate cancer — fatal and metastatic (206 of the 283 men).

"And the longer men used cholesterol-lowering drugs, the lower their risk," she added.

By the end of the study, more than 90 percent of men taking cholesterol-lowering drugs opted for statins, as opposed to other cholesterol-lowering drugs. "Since most of these study participants were taking statins during the time that we saw the highest levels of risk reduction, we believe that statins more than any of the other cholesterol-lowering drugs may have the biggest risk-reduction effects, but more studies are necessary to validate this," Platz said.

Statins lower cholesterol by blocking an enzyme that controls its assembly. There are clues to suggest key cellular pathways involved in cancer-risk reduction may include statins' effects on testosterone production, cell signaling and inflammation. Or the drugs may play a role in changing prostate cancer cell membranes, which are rich in cholesterol.

Prostate cancer is the leading cancer in American men. It strikes more than 230,000 U.S. men annually and kills more than 30,000.

Additional research investigators include Michael F. Leitzmann, from the National Cancer Institute; Kala Visvanathan, from Johns Hopkins; and Meir J. Stampfer, Walter C. Willett, Eric B. Rimm and Edward Giovannucci from Harvard.


The Gazette | The Johns Hopkins University | Suite 540 | 901 S. Bond St. | Baltimore, MD 21231 | 443-287-9900 |